| Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options M Koufopoulou, PAP Miranda, P Kazmierska, S Deshpande, P Gaitonde Cancer treatment reviews 89, 102072, 2020 | 21 | 2020 |
| Evaluation of PCMH model adoption on teamwork and impact on patient access and safety N Khanna, FT Shaya, P Gaitonde, A Abiamiri, B Steffen, D Sharp Journal of primary care & community health 8 (2), 77-82, 2017 | 16 | 2017 |
| Factors associated with use of disease modifying agents for rheumatoid arthritis in the National Hospital and Ambulatory Medical Care Survey P Gaitonde, LM Bozzi, FT Shaya Seminars in arthritis and rheumatism 47 (5), 649-653, 2018 | 14 | 2018 |
| A quality-adjusted survival (Q-TWiST) analysis to assess benefit-risk of acalabrutinib versus idelalisib/bendamustine plus rituximab or ibrutinib among relapsed/refractory (R/R … JF Seymour, P Gaitonde, U Emeribe, L Cai, AR Mato Blood 138, 3722, 2021 | 7 | 2021 |
| Characteristics of schools of pharmacy associated with a successful PGY1 residency match AA Feemster, P Gaitonde, H Vu, F Shaya Currents in Pharmacy Teaching and Learning 10 (9), 1205-1210, 2018 | 7 | 2018 |
| Relationship between depression, self-care behaviors, and treatment success among older medicare beneficiaries with type 2 diabetes P Gaitonde, FT Shaya Journal of Pharmaceutical Health Services Research 7 (4), 241-245, 2016 | 5 | 2016 |
| Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States T Munir, V Genovez, V Genestier, K Ryan, B Liljas, P Gaitonde Expert Review of Pharmacoeconomics & Outcomes Research 23 (5), 579-589, 2023 | 3 | 2023 |
| Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients … MS Davids, U Emeribe, P Gaitonde, L Cai Blood 138, 2633, 2021 | 3 | 2021 |
| Cost-effectiveness of acalabrutinib monotherapy compared with chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukemia T Munir, P Gaitonde, C Waweru Blood 136, 13-14, 2020 | 3 | 2020 |
| Characteristics of pharmacy students associated with a successful PGY1 residency match A Feemster, M Calabrese, P Gaitonde, F Shaya Medical Science Educator 27, 607-611, 2017 | 3 | 2017 |
| Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors P Gaitonde, V Chirikov, S Kelkar, B Liljas Cancer Management and Research, 3421-3435, 2022 | 2 | 2022 |
| Economic and Productivity Consequences Associated with Rheumatoid Arthritis Among Non-Institutionalized Individuals in The United States P Gaitonde, FT Shaya Value in Health 19 (3), A77, 2016 | 1 | 2016 |
| Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) Conference 2015: Patient-Focused Drug Development (PFDD) EM Perfetto, EM Oehrlein, C Anyanwu, M Burcu, P Gaitonde, ML Hanna, ... | 1 | 2015 |
| Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia JP Sharman, P Miranda, J Roos, U Emeribe, L Cai, B Liljas, P Gaitonde Leukemia & Lymphoma 64 (7), 1243-1252, 2023 | | 2023 |
| Matching-Adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma P Gaitonde, L Cai, P de Miranda, J Roos, S Rule, ML Wang Blood 140 (Supplement 1), 3646-3647, 2022 | | 2022 |
| CO22 Adjusting Survival Data for Treatment Crossover in the ELEVATE-TN Trial By Using a Historical Cohort of Patients Treated with Chemoimmunotherapy in Front-Line Chronic … P Gaitonde, B Liljas, P Miranda Value in Health 25 (7), S308, 2022 | | 2022 |
| PB1877: ADJUSTING SURVIVAL DATA FOR TREATMENT CROSSOVER IN THE ELEVATE-TN TRIAL BY USING A HISTORICAL COHORT OF PATIENTS TREATED WITH CHEMOIMMUNOTHERAPY IN FRONT-LINE CHRONIC … P Gaitonde, B Liljas, B Shaw, P Miranda HemaSphere 6, 1757-1758, 2022 | | 2022 |
| Total Healthcare Expenditures Associated with Biological Anti-Rheumatic Drugs Use Among Medicare Beneficiaries with Rheumatoid Arthritis P Gaitonde, F Shaya Value in Health 21, S263, 2018 | | 2018 |
| Utilization and Cost of Biologic Disease Modifying Antirheumatic Drugs among Medicare Beneficiaries with Rheumatoid Arthritis P Gaitonde University of Maryland, Baltimore, 2018 | | 2018 |
| Erratum to: Characteristics of Pharmacy Students Associated with a Successful PGY1 Residency Match A Feemster, M Calabrese, P Gaitonde, F Shaya Medical Science Educator 27, 863-863, 2017 | | 2017 |
